BioPharm International
CONTINUE TO SITE >

OR WAIT 15 SECS

BioPharm International
Spotlight
Topic
News
Publications
Resources
Webcasts
Subscribe

  • About Us
  • Advertise
  • Editorial Information
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and BioPharm International. All rights reserved.

Spotlight
  • COVID-19 Update
  • Analytics
  • Development
  • Downstream Processing
  • Manufacturing
  • Outsourcing
  • Quality/GMPs
  • Upstream Processing
  • 2020 Bio/Pharma Virtual Congress
TopicSee All >
  • Analytical Methods
  • BioBusiness
  • Cell Culture/Fermentation
  • Continuous Processing
  • Drug Delivery
  • Fill/Finish
  • Formulation
  • Process Chromatography
  • Process Control/PAT
  • Process Development
  • QA/QC
  • Separation and Purification
  • Single-Use Systems
  • Supply Chain
  • About Us
  • Advertise
  • Editorial Information
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.

Entirely New Flu Vaccine Needed Next Year, Says WHO

March 12, 2008
BioPharm International Editors
BioPharm International Editors

According to a report released by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), the three most common types of influenza strains have changed in such a way that they are now showing signs of resistance to the Tamiflu and Relenza vaccines

According to a report released by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), the three most common types of influenza strains have changed in such a way that they are now showing signs of resistance to the Tamiflu and Relenza vaccines.

For the first time in 20 years, the CDC is recommending a complete reformulation of the vaccine. In its FluView report for the week ending March 1, the CDC announced its recommendations for the formulation of the influenza vaccine for the 2008-2009 flu season. The recommendations are announced a year in advance because of the lengthy process by which the vaccines are produced. All three of the inactivated strains of the virus that were suggested for the 2008-2009 formulation are different from the current formulation.

CDC Q&A on Influenza FluView for March 1, 2008

Related Content:

News